Lexeo Therapeutics
Clinical trials sponsored by Lexeo Therapeutics, explained in plain language.
-
Gene therapy targets heart failure in rare genetic disease
Disease control OngoingThis early-stage study tests a one-time gene therapy called LX2006 in 8 people with Friedreich's ataxia who also have heart muscle disease. The therapy delivers a working copy of the frataxin gene directly to heart cells to improve heart function. Researchers will monitor safety …
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 26, 2026 10:25 UTC
-
Gene therapy for rare heart disease: Long-Term safety check begins
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received LX2020 gene therapy for arrhythmogenic cardiomyopathy caused by a PKP2 gene mutation. Researchers will monitor participants for years to see if the treatment remains safe and continues to work. The goal is to understand long-term …
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Gene therapy trial hopes to fix heart muscle in rare genetic disease
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 in 10 adults with a rare, inherited heart condition (PKP2-ACM) that can cause dangerous heart rhythms and heart failure. The therapy is given once through a vein and aims to deliver a working copy of the PKP2 gene to heart…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:44 UTC